The short version of MC4R fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
==== Operation Sem Desconto ==== On 23 April 2025, the Federal Police (PF) and the Comptroller General of the Union (CGU) launched Operation Sem Desconto, to combat a criminal scheme that, since 2019, had been promoting the diversion of more than 6.3 billion reais from retirement and pension payments made by the National Institute of Social Security (INSS), by using entities constituted solely for the purpose of including payroll deductions directly in the payment of their benefits, without the beneficiary's authorization. The legal authorization for deduction of association dues directly from payments to retirees and pensioners has existed since 1991. According to the CGU and the Ministry of Justice and Public Security, class entities, such as associations and unions, formalized Technical Cooperation Agreements (ACT) with the INSS, which justified payroll deductions from the agency's beneficiaries. However, the authorization for the deductions was, in many cases, forged. In this way, the CGU began a series of investigations after identifying the surge in the collection of the entities and in the deducted amounts from 2023 onward. Among the reasons for the increase in deductions are the loosening of rules, motivated by lobbies in the National Congress, failures by the INSS in control and oversight, and political appointments to the agency.
23 June – 2024 United Kingdom general election date betting controversy The Sunday Times reports that Nick Mason, the Conservative Party's chief data officer, has become the fourth person to face investigation by the Gambling Commission for alleged betting on the date of the election. Mason denies any wrongdoing. BBC News reports that the Gambling Commission's investigation involves more people than those already named. The constituency office of Labour Walthamstow candidate Stella Creasy is damaged overnight by vandals. UTV airs a general election debate featuring candidates from Northern Ireland's five main political parties: The Democratic Unionist Party's leader Gavin Robinson, Sinn Féin's John Finucane, Social Democratic and Labour Party leader Colum Eastwood, Alliance Party leader Naomi Long and Ulster Unionist Party deputy leader Robbie Butler. 24 June – Sunak says that he is "not aware of any other" Conservative candidates being investigated by the Gambling Commission. The Institute for Fiscal Studies says that it will be a "considerable surprise" if UK taxes do not rise in the next five years and says the two main parties are "ducking" the issue in their manifestos. The Scottish Conservatives launch their election manifesto, which includes plans to improve teachers' pay, cut the backlog of NHS waiting lists, and to beat the SNP. The Democratic Unionist Party launches its 2024 election manifesto, with policies including greater access to healthcare, opposition to assisted suicide and the removal of trade barriers within the UK.
It is a member of the small pentraxins family (also known as short pentraxins). The polypeptide encoded by this gene has 224 amino acids. The full-length polypeptide is not present in the body in significant quantities due to signal peptide, which is removed by signal peptidase before translation is completed. The complete protein, composed of five monomers, has a total mass of approximately 120,000 Da. In serum, it assembles into stable pentameric structure with a discoid shape.
Sources: en.wikipedia.org
== Secretion == A typical adult human stomach will secrete about 1.5 liters of gastric juice daily. Gastric juice is the combination of gastric gland secretions including the main component of hydrochloric acid (gastric acid), gastric lipase and pepsinogen. Once in the stomach pepsinogen is changed by gastric acid to the digestive enzyme pepsin adding this enzyme to the gastric juice. In humans, the pH of gastric acid is between one and three, much lower than most other animals, but is very similar to that of carrion eating carnivores, needing extra protection from ingesting pathogens. Gastric acid secretion is produced in several steps. Chloride and hydrogen ions are secreted separately from the cytoplasm of parietal cells and mixed in the canaliculi. This creates a negative potential of between −40 and −70 mV across the parietal cell membrane that causes potassium ions and a small number of sodium ions to diffuse from the cytoplasm into the parietal cell canaliculi. Gastric acid is then secreted along with other gland secretions into the gastric pit for release into the stomach lumen. The enzyme carbonic anhydrase catalyses the reaction between carbon dioxide and water to form carbonic acid. This acid immediately dissociates into hydrogen and bicarbonate ions. The hydrogen ions leave the cell through H+/K+ ATPase antiporter pumps. At the same time, sodium ions are actively reabsorbed. This means that the majority of secreted K+ (potassium) and Na+ (sodium) ions return to the cytoplasm.
== Diaphragm and peristaltic pumps == In order to avoid leakage at the packing or seal particularly when a liquid is dangerous, toxic, or noxious, diaphragm pumps are used for metering. Diaphragm pumps have a diaphragm through which repeated compression/decompression motion is transmitted. The liquid does not penetrate through the diaphragm, so the liquid inside the pump is sealed off from the outside. Such motion changes the volume of a chamber in the pump head so that liquid enters through an inlet check valve during decompression and exits through an outlet check valve during compression, in a manner similar to piston pumps. Diaphragm pumps can also be made which discharge at fairly high pressure. Diaphragm metering pumps are commonly hydraulically driven. Peristaltic pumps use motor-driven rollers to roll along flexible tubing, compressing it to push forward a liquid inside. Although peristaltic pumps can be used to meter at lower pressures, the flexible tubing is limited in the level of pressure it can withstand.
== Chemical classes == As hormones are defined functionally, not structurally, they may have diverse chemical structures. Hormones occur in multicellular organisms (plants, animals, fungi, brown algae, and red algae). These compounds occur also in unicellular organisms, and may act as signaling molecules however there is no agreement that these molecules can be called hormones.
Sources: en.wikipedia.org
==== Oligonucleotide therapeutics ==== Unlike small-molecule drugs, approved RNAi-based therapeutics such as siRNA drugs do not significantly induce or inhibit cytochrome P450 (CYP) enzymes, and therefore require distinct frameworks for evaluating drug–drug interactions (DDIs). Several interaction mechanisms relevant to oligonucleotide drugs have been identified:
It served as a model for school systems across the nation. Dr. Iris T. Metts, the superintendent of schools at the time, formulated an ambitious plan to actually expand the magnet programs in PGCPS, as well as reassign magnet programs that weren't performing well at one location, to other schools. Due to long and highly publicized in-house issues between Metts and the board of education, Metts was replaced by Dr. Andre Hornsby at the end of her contract with PGCPS. When Hornsby arrived, he essentially reversed the decision that Metts had made, in regards to the future of the county's magnet programs, and he decided to instead eliminate most of the school system's magnet programs, most of which had been identified as under-performing for several years. Ten magnet programs were identified for elimination, which proved extremely controversial because some of the proposed eliminated programs were located at sites in which the program in question had been extremely successful, such as the Academic Center magnet program at Martin Luther King, Jr. Academic Center, which had been the highest performing middle school in the system for several years and also was a blue ribbon school. Despite the opposition by parents, in 2006 the magnet programs in PGCPS underwent an overhaul, and most of the magnets were eliminated. A few programs that were determined to be "successful" were either expanded and replicated at other locations, or consolidated and relocated to a dedicated magnet school that would serve large geographic areas of the county.
Examples of unsaturated fatty acids are palmitoleic acid, oleic acid, myristoleic acid, linoleic acid, and arachidonic acid. Foods containing unsaturated fats include avocado, nuts, olive oil, and vegetable oils, such as canola. Meat products contain both saturated and unsaturated fats. The amount of unsaturated fat consumed should be in a range of about 20-35% of one's daily caloric intake. Most foods contain both unsaturated and saturated fats.
This advancement could allow for assisted transport, making synthetic platelets a viable option in healthcare locations with limited resources, such as rural hospitals, ambulances, and battlefield settings. While preclinical results are encouraging, challenges remain in the large-scale clinical translation of synthetic platelets. Reproducibility, large-scale production, and safety issues must be addressed to gain regulatory approval and commercial viability. Researchers continue to refine synthetic platelet formulations by maximizing circulation time, stability, and biodegradability while minimizing undesirable immune responses. Additionally, studies have shown that synthetic platelets are excreted from the body within hours if they do not reach a wound site, which reduces the risk of unintended clotting in other parts of the body.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.